Drug Search Results
More Filters [+]

Alvelestat

Alternative Names: alvelestat, azd9668, mph-966, mph966, mph 966
Latest Update: 2024-06-14
Latest Update Note: News Article

Product Description

for the Treatment of ALpha-1 ANTitrypsin Deficiency. Alvelestat (MPH966, formerly AZD9668) is a potent, selective, and reversible, oral inhibitor of human NE. Suppression of NE is expected to reduce lung damage and may slow disease progression. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03679598)

Mechanisms of Action: ELA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Fast Track -
Orphan Drug - alpha 1-Antitrypsin Deficiency *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Alvelestat

Countries in Clinic: Belgium, Canada, Denmark, Poland, Spain, Sweden, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: COVID-19|Chronic Obstructive Pulmonary Disease|Emphysema|alpha 1-Antitrypsin Deficiency

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ATALANTa

P2

Completed

alpha 1-Antitrypsin Deficiency|Emphysema|Chronic Obstructive Pulmonary Disease

2023-11-30

ASTRAEUS

P2

Completed

Chronic Obstructive Pulmonary Disease|Emphysema|alpha 1-Antitrypsin Deficiency

2022-03-02

COSTA

P2

Completed

COVID-19

2021-10-29

Recent News Events